Member Info for Leggster

Very encouraging to see the additional raise, my worry with SAR has been cash runway and poor financial decisions. The dilution to remove the runway concerns is hugely encouraging. The payments in shares also show a thumbs up from the recipients which I personally find encouraging.

GLA

IMO the news today although a little deflating, I had hoped for a licence or TO, I do still see it as a positive step, the dilution for me is at an acceptable level, HNWIs are again in play, an institution was involved so we are clearly back in the sphere of being able to access funding options, further delay is frustrating but the strengthend cash position will improve the companies hand in negotiations. FWIW I suspect discussions are ongoing and this is a statement in the negotiation dance to show that a deal is not the only option. Hopefully Parker is pushing parties to a best and final offer. Still lots to hold interest here and the immediate dilution risk is resolved. GLA

Deals take time and even once heads of terms and high level commercials agreed the drafting of an agreement itself takes a few months. Normally until executed parties do not announce a deal. I personally think it likely with the radio silence that a deal of some sort has probably been agreed and that we may well now be in rounds of page turning on any agreement before it can be announced. GLA

Would be great to finally get some visibility on what is happening to 737. As you say not long now until December and we get some insight. GLA

The attendance at BIO is still on the site if you navigate through the menu to upcoming events.

Often SARs preferred day to release news, would be pleasant to wake up to a red dot......

Aber, I also tend to agree all of the pointers suggests talks are in flight, exciting times and news at any point, equally FWIW I can't see a dilutive raise being in the mix as I feel this would have been announced by now and we have already been signposted several times by the board that the test data is good. GLA

Yes encouraging to see the derampers out early, it confirms news is on its way, soon.

I am an optimist and choose to believe this SP will recover, why because the science to date has been sound, patent protection is strong, the founders are highly credible, the addressable markets are numerous and valuable, we no we passed the ethics committee. In a short time now we will have far more news. However even as an optimist I want a partner via licencevor a takeover I am nervous of us going alone as it is clear that SAR have struggled managing cash runway effectively to date. I still though see a bright future and expect the news to be good. GLA

Not many days of Q3 left now, will SAR keep inside their timeliness guidance and release info around the test data or will be left waiting into Q4. We will soon know, good data as we expect then this is massively under price. Hopefully Mr Parker is Beavering away in the background and will have good news for us in the near future. GLA

Hopefully the first in a number of positive pieces of news. I was pleased to see that the general comments were all bullish... GLA

Potnak, I will first declare that my preference is a TO however in reality I think that both are possible outcomes at this juncture, price will be much higher after a successful further trial and I would be seriously considering if a potential licencee simply buying the whole company to reduce future cost and to give me access to both molecules. However I will be happy with either outcome licence or TO, I would though be concerned if we try to raise and go alone. GLA

I agree for me some sort deal now should be an essential aim, it fits with strategy and I am not confident that SAR can manage a Ph 2 trial effectively. A licence or TO are what I want to see at this point. GLA

I am still of the personal opinion that a TO at this point (assuming the data is good) is an attractive option to a pharma. Clearly waiting for Phase 2 results derisks further, but with good results for review and the knowledge that Tyk2 molecules are already understood there is a trade off between the higher potential cost from licence against the fixed cost of a TO. If I were involved in evaluating the options I would certainly be seriously considering a straight buyout alongside a licence and IMO there are compelling reasons for a TO at this point to be actively assessed. GLA

I share SOG's viewpoint that this period of silence is for both analysing the data and negotiating the way forward. Frustrating though the wait is in the reality of deal negotiations the time is still relatively short, interpreting data, discussing with interested parties, agreeing heads of terms and then actual draft a contract all take time, though I would rather say that a deal will be announced imminently in reality it will probably take sometime yet. But it would be nice to get some updates on topline data results for example or even some tweets to keep shareholders morale up. GLA

It increases my confidence that news is close as the negative noise increases. The science has been good to date I choose to trust that a positive outcome is heading our way and I still believe 737 news will be materially SP additive when it drops. GLA

What is certain is that volume is currently negligible, the vast majority are holding for news and with some positive data, SP growth seems a very possible outcome GLA

Laz, thanks for the clarity and let's hope it is an iceberg, the stability is very out of the norm so I do tend to believe that there must be a cause.

Hopefully news inbound shortly to deliver the pivot the SP needs.

This period of dead calm on the share price feels very odd for SAR, saw comments earlier this week re a submarine buyer. It will be a very slow process for them though with extremely low daily volume to feed off. News will come but the waiting is tedious GLA

It's a bit like the Game of Thrones strapline but instead of winter it's 'News is coming' we know for SAR it's going to be a big event but we don't know exactly what it is and many don't believe it's coming at all, GLA